{"id":"moxifloxacin-0-5-hci-ophthalmic-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctivitis"},{"rate":null,"effect":"Decreased visual acuity"},{"rate":null,"effect":"Dry eye"},{"rate":null,"effect":"Ocular discomfort or irritation"},{"rate":null,"effect":"Keratitis"}]},"_chembl":{"chemblId":"CHEMBL1200735","moleculeType":"Small molecule","molecularWeight":"437.90"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a broad-spectrum fluoroquinolone, moxifloxacin works by binding to and inhibiting bacterial DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for DNA replication and transcription. This dual inhibition leads to rapid bactericidal activity against a wide range of gram-positive and gram-negative ocular pathogens. When formulated as an ophthalmic solution, it achieves high local concentrations in ocular tissues to treat bacterial infections of the eye.","oneSentence":"Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and causing bacterial cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:55:56.120Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial conjunctivitis"},{"name":"Bacterial corneal ulcer"},{"name":"Prophylaxis of bacterial infection following ocular surgery"}]},"trialDetails":[{"nctId":"NCT00874887","phase":"PHASE4","title":"A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-03","conditions":"Anti-biotic Resistance","enrollment":66}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vigamox®"],"phase":"marketed","status":"active","brandName":"moxifloxacin 0.5% HCI ophthalmic solution","genericName":"moxifloxacin 0.5% HCI ophthalmic solution","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and causing bacterial cell death. Used for Bacterial conjunctivitis, Bacterial corneal ulcer, Prophylaxis of bacterial infection following ocular surgery.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}